Lymphoma
Conditions
Keywords
recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult Burkitt lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy combined with rituximab in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.
Detailed description
OBJECTIVES: * Determine the chemosensitivity rate in patients with recurrent or refractory non-Hodgkin's lymphoma treated with ifosfamide, carboplatin, and etoposide (ICE) in combination with rituximab. * Determine whether the addition of rituximab changes the toxicity profile of the ICE chemotherapy regimen in these patients. OUTLINE: Patients receive rituximab IV on days 1, 8, and 15 and ifosfamide IV over 1 hour, etoposide IV over 2 hours, and carboplatin IV on days 2-4. Treatment continues every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who are not candidates for autologous stem cell transplantation may receive 1-4 more courses of chemotherapy without rituximab. Patients are followed at 1 month. PROJECTED ACCRUAL: A total of 19-39 patients will be accrued for this study within 2 years.
Interventions
BIOLOGICALrituximab
DRUGcarboplatin
DRUGetoposide
DRUGifosfamide
Sponsors
National Cancer Institute (NCI)
University of Nebraska
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
19 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed recurrent or refractory B-cell non-Hodgkin's lymphoma o CD20 positive * Bidimensionally measurable or evaluable disease * 19 years old and over * ECOG 0-2 or Karnofsky 70-100% * Life expectancy at least 3 months * WBC at least 3,000/mm3 * Granulocyte count at least 1,000/mm3 * Platelet count at least 100,000/mm3 * Bilirubin no greater than 1.5 times upper limit of normal(ULN) * AST or ALT no greater than 2.5 times ULN * Creatinine no greater than 1.5 mg/dL * Fertile patients must use effective contraception * Concurrent non-steroidal hormonal therapy allowed for non-disease related conditions (e.g., insulin for diabetes)
Exclusion criteria
* No myelodysplastic syndrome or chronic myeloid leukemia * Not pregnant or nursing/negative pregnancy test * No other prior malignancy except curatively treated basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix * No active serious infection * No other concurrent serious medical condition that would preclude study * No prior bone marrow or peripheral blood stem cell transplantation for non-Hodgkin's lymphoma * No other concurrent chemotherapy * No concurrent corticosteroids except transient administration as antiemetic * No concurrent radiotherapy * No other concurrent investigational therapy * No other concurrent antitumor agents
Countries
United States
Outcome results
None listed